...
首页> 外文期刊>Journal of the American Society of Hypertension : >Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study
【24h】

Effect of dual compared to no or single renin-angiotensin system blockade on risk of renal replacement therapy or death in predialysis patients: PREPARE-2 study

机译:与无肾素-血管紧张素系统阻断相比,双重肾素-血管紧张素系统阻断对透析前患者肾脏替代治疗或死亡风险的影响:PREPARE-2研究

获取原文
获取原文并翻译 | 示例

摘要

Abstract Current guidelines on hypertension treatment in chronic kidney disease (CKD) patients discourage combined angiotensin-converting enzyme inhibitor (ACEi) and angiotensin II receptor blocker (ARB) use due to the risk of an increased kidney function decline. However, dual compared to single renin-angiotensin system (RAS) blockade may have more efficacy with regard to hypertension and proteinuria. Among incident predialysis patients (CKD 4-5), we compared dual with no or single RAS blockade regarding kidney function decline and risk of renal replacement therapy (RRT) or death. In a multicenter cohort study, 495 incident predialysis patients (>18 years) were included between 2004 and 2011 and followed until RRT, death, or October 2016. At baseline, patients were divided into four categories: nonuser, single or dual user of ACEi and/or ARB. Cox models were used to estimate the hazard ratio for the combined end point RRT or death. Differences in decline of kidney function among the four drug groups were compared with a linear mixed model. A total of 119 patients were nonusers, 164 ACEi users, 133 ARB users, and 79 dual RAS users. Compared to nonusers, the multivariable adjusted hazard ratio (95 confidence interval) for the combined end point was 0.75 (0.65 to 0.86) for ACEi users, 0.87 (0.76 to 1.00) for ARB users, and 0.79 (0.67 to 0.94) for dual RAS users. The average annual decline in kidney function did not differ among the four groups. We observed in predialysis patients that compared to no RAS blockade, both dual RAS blockade and single ACEi use were associated with about 20-25 lower risk of RRT or death, without difference in kidney function decline. Highlights In predialysis patients, dual compared to no renin-angiotensin system blockade: ? may lower the risk of end-stage renal disease or death; ? does not increase kidney function decline; ? may be useful to treat hypertension or proteinuria. >
机译:摘要 目前慢性肾脏病(CKD)患者高血压治疗指南不鼓励联合使用血管紧张素转换酶抑制剂(ACEi)和血管紧张素II受体阻滞剂(ARB),因为存在肾功能下降增加的风险。然而,与单药肾素-血管紧张素系统 (RAS) 阻断相比,双重阻断在高血压和蛋白尿方面可能更有效。在透析前患者(CKD 4-5)中,我们比较了双重与无或单次RAS阻断在肾功能下降和肾脏替代疗法(RRT)或死亡风险方面的影响。在一项多中心队列研究中,纳入了 2004 年至 2011 年间的 495 例透析前患者(>18 岁),并随访至 RRT、死亡或 2016 年 10 月。在基线时,患者分为四类:非使用者、ACEi 和/或 ARB 的单一或双重使用者。Cox模型用于估计联合终点RRT或死亡的风险比。将四组药物之间肾功能下降的差异与线性混合模型进行比较。共有 119 例患者为非使用者,164 例为 ACEi 用户,133 例为 ARB 用户,79 例为双 RAS 用户。与非用户相比,ACEi用户的合并终点的多变量调整风险比(95%置信区间)为0.75(0.65至0.86),ARB用户为0.87(0.76至1.00),双RAS用户为0.79(0.67至0.94)。四组肾功能年均下降无差异。我们在透析前患者中观察到,与不使用 RAS 阻断相比,双重 RAS 阻断和单次使用 ACEi 都与 RRT 或死亡风险降低约 20%-25% 相关,肾功能下降没有差异。亮点 在透析前患者中,与无肾素-血管紧张素系统阻断相比,双重阻断:?可降低终末期肾病或死亡的风险; ?不增加肾功能下降; ?可能有助于治疗高血压或蛋白尿。]]>

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号